No Data
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Jazz Pharmaceuticals Plc's (NASDAQ:JAZZ) Subdued P/E Might Signal An Opportunity
BofA Securities Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $213
Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect?
Express News | Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (Calcium, Magnesium, Potassium, and Sodium Oxybates) Oral Solution and Epidiolex® (Cannabidiol) at American Academy of Neurology Annual Meeting
Jazz Pharmaceuticals (JAZZ) Gets a Buy From Jefferies
